Strategic Funding Serina has recently secured multiple rounds of private equity financing totaling at least $15 million across 2025, signaling strong investor confidence and potential for renewed partner commitments or co-development opportunities in their POZ Platform drug delivery programs.

POZ Platform The proprietary POZ water-soluble polymer delivery technology is a core differentiator. This presents opportunities to partner on formulation development, optimization of Neurology and Pain candidates, and potential expansion into oncology or cannabinoid therapies leveraging the POZ platform.

Neurology Focus Active work in Parkinson’s disease and neurological conditions creates potential sales conversations with contract research and manufacturing organizations, patient support programs, and potential licensing discussions around POZ-enabled CNS drug candidates.

Clinical-stage Growth With a clinical-stage pipeline and recent leadership changes, there is momentum for partnerships around manufacturing support, late-stage optimization, and potential acquisition discussions for assets via CRO/CDMO collaboration or shared manufacturing arrangements.

Strategic Partnerships Recent collaboration activity around enFuse for Parkinson’s indicates openness to alliance models. Target potential partners in neurodegenerative, pain, and oncology spaces seeking novel delivery technologies or co-development with a nimble, privately held biotech.